LOS ANGELES, CA--(Marketwire - Jun 21, 2011) - Senesco Technologies (NYSE Amex: SNT) announced after-hours on Monday that the Company had been informed by U.S. regulators that all clinical hold issues on Senesco's Investigational New Drug application for their lead product candidate SNS01-T had been lifted.